Multicenter analysis of immune biomarkers and heart transplant outcomes: Results of the clinical trials in organ transplantation-05 study

American Journal of Transplantation

Volumn 16, Issue 1, 2016, Pages 121-136

  Starling, R C ^a   Stehlik, J ^b   Baran, D A ^c   Armstrong, B ^d   Stone, J R ^e   Ikle, D ^d   Morrison, Y ^f   Bridges, N D ^f   Putheti, P ^g   Strom, T B ^g   Bhasin, M ^g   Guleria, I ^h,i   Chandraker, A ^h   Sayegh, M ^h   Daly, K P ⁱ   Briscoe, D M ⁱ   Heeger, P S ^j  

^a CLEVELAND CLINIC LERNER COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF UTAH HEALTH SCIENCES CENTER   (United States)

^c NEWARK BETH ISRAEL MEDICAL CENTER   (United States)

^d Rho   (United States)

^e MASSACHUSETTS GENERAL HOSPITAL   (United States)

^f NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^g BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^h BRIGHAM AND WOMEN S HOSPITAL   (United States)

ⁱ BOSTON CHILDREN S HOSPITAL   (United States)

^j MOUNT SINAI SCHOOL OF MEDICINE   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENIC PROTEIN; AUTOANTIBODY; BIOLOGICAL MARKER; ENDOTHELIN 1; HLA ANTIBODY; VASCULOTROPIN C; MESSENGER RNA; VASCULOTROPIN A; VEGFA PROTEIN, HUMAN;

ACUTE GRAFT REJECTION; ADULT; ALLOIMMUNITY; ARTICLE; BIOPSY PROVEN ACUTE REJECTION; CARDIAC ALLOGRAFT VASCULOPATHY; CARDIAC GRAFT REJECTION; CELLULAR IMMUNITY; COHORT ANALYSIS; FEMALE; GENE EXPRESSION; GRAFT FAILURE; GRAFT RECIPIENT; HEART TRANSPLANTATION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INTRAVASCULAR ULTRASOUND; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; RETRANSPLANTATION; ADVERSE EFFECTS; CASE CONTROL STUDY; CLINICAL TRIAL; CLINICAL TRIAL (TOPIC); COMPARATIVE STUDY; CORONARY ARTERY DISEASE; GENE EXPRESSION PROFILING; GENETICS; GRAFT REJECTION; HEART DISEASES; METABOLISM; MIDDLE AGED; PROSPECTIVE STUDY; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

ADULT; BIOMARKERS; BLOTTING, WESTERN; CASE-CONTROL STUDIES; CLINICAL TRIALS AS TOPIC; CORONARY ARTERY DISEASE; ENDOTHELIN-1; FEMALE; GENE EXPRESSION PROFILING; GRAFT REJECTION; HEART DISEASES; HEART TRANSPLANTATION; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84956939821     PISSN: 16006135     EISSN: 16006143     Source Type: Journal    
DOI: 10.1111/ajt.13422     Document Type: Article

References (85)

1. Lund LH, Edwards LB, Kucheryavaya AY, et al., The registry of the International Society for Heart and Lung Transplantation: Thirty-first official adult heart transplant report-2014; focus theme: Retransplantation. J Heart Lung Transplant 2014; 33: 996-1008.
2. Lund LH, Edwards LB, Kucheryavaya AY, et al., The registry of the International Society for Heart and Lung Transplantation: Thirtieth Official Adult Heart Transplant Report-2013; focus theme: Age. J Heart Lung Transplant 2013; 32: 951-964.
3. Pham MX, Teuteberg JJ, Kfoury AG, et al., Gene-expression profiling for rejection surveillance after cardiac transplantation. N Engl J Med 2010; 362: 1890-1900.
4. Gonzalez-Stawinski GV, Cook DJ, Chui J, et al., A comparative analysis between survivors and nonsurvivors with antibody mediated cardiac allograft rejection. J Surg Res 2007; 142: 233-238.
5. Yamani MH, Taylor DO, Haire C, Smedira N, Starling RC,. Post-transplant ischemic injury is associated with up-regulated AlloMap gene expression. Clin Transplant 2007; 21: 523-525.
6. Yamani MH, Taylor DO, Rodriguez ER, et al., Transplant vasculopathy is associated with increased AlloMap gene expression score. J Heart Lung Transplant 2007; 26: 403-406.
7. Yamani MH, Cook DJ, Rodriguez ER, et al., Increased expression of angiotensin II type 1 receptor (AGTR1) in heart transplant recipients with recurrent rejection. J Heart Lung Transplant 2006; 25: 1283-1289.
8. Yousufuddin M, Yamani MH,. The renin-angiotensin hypothesis for the pathogenesis of cardiac allograft vasculopathy. Int J Cardiol 2004; 95: 123-127.
9. Fahmy NM, Yamani MH, Starling RC, et al., Chemokine and receptor-gene expression during early and late acute rejection episodes in human cardiac allografts. Transplantation 2003; 75: 2044-2047.
10. Ferri C, Properzi G, Tomassoni G, et al., Patterns of myocardial endothelin-1 expression and outcome after cardiac transplantation. Circulation 2002; 105: 1768-1771.
11. Yamani MH, Masri CS, Ratliff NB, et al., The role of vitronectin receptor (alphavbeta3) and tissue factor in the pathogenesis of transplant coronary vasculopathy. J Am Coll Cardiol 2002; 39: 804-810.
12. Yen MH, Pilkington G, Starling RC, et al., Increased tissue factor expression predicts development of cardiac allograft vasculopathy. Circulation 2002; 106: 1379-1383.
13. Azzawi M, Hasleton PS, Turner DM, et al., Tumor necrosis factor-alpha gene polymorphism and death due to acute cellular rejection in a subgroup of heart transplant recipients. Hum Immunol 2001; 62: 140-142.
14. Baan CC, Balk AH, Dijke IE, et al., Interleukin-21: An interleukin-2 dependent player in rejection processes. Transplantation 2007; 83: 1485-1492.
15. Dengler TJ, Zimmermann R, Braun K, et al., Elevated serum concentrations of cardiac troponin T in acute allograft rejection after human heart transplantation. J Am Coll Cardiol 1998; 32: 405-412.
16. Dijke IE, Caliskan K, Korevaar SS, et al., FOXP3 mRNA expression analysis in the peripheral blood and allograft of heart transplant patients. Transpl Immunol 2008; 18: 250-254.
17. Keslar K, Rodriguez ER, Tan CD, Starling RC, Heeger PS,. Complement gene expression in human cardiac allograft biopsies as a correlate of histologic grade of injury. Transplantation 2008; 86: 1319-1321.
18. Perez-Villa F, Benito B, Llancaqueo M, Cuppoletti A, Roig E,. Elevated levels of serum interleukin-6 are associated with low grade cellular rejection in patients with heart transplantation. Transplant Proc 2006; 38: 3012-3015.
19. Melter M, Exeni A, Reinders ME, et al., Expression of the chemokine receptor CXCR3 and its ligand IP-10 during human cardiac allograft rejection. Circulation 2001; 104: 2558-2564.
20. Reinders ME, Fang JC, Wong W, Ganz P, Briscoe DM,. Expression patterns of vascular endothelial growth factor in human cardiac allografts: Association with rejection. Transplantation 2003; 76: 224-230.
21. Seki A, Fishbein MC,. Predicting the development of cardiac allograft vasculopathy. Cardiovasc Pathol 2014; 23: 253-260.
22. Barr ML, Cohen DJ, Benvenisty AI, et al., Effect of anti-HLA antibodies on the long-term survival of heart and kidney allografts. Transplant Proc 1993; 25 (1 Pt 1): 262-264.
23. Ciubotariu R, Liu Z, Colovai AI, et al., Persistent allopeptide reactivity and epitope spreading in chronic rejection of organ allografts. J Clin Invest 1998; 101: 398-405.
24. Itescu S, Tung TC, Burke EM, et al., An immunological algorithm to predict risk of high-grade rejection in cardiac transplant recipients. Lancet 1998; 352: 263-270.
25. Reed EF, Hong B, Ho E, Harris PE, Weinberger J, Suciu-Foca N,. Monitoring of soluble HLA alloantigens and anti-HLA antibodies identifies heart allograft recipients at risk of transplant-associated coronary artery disease. Transplantation 1996; 61: 566-572.
26. Poggio ED, Roddy M, Riley J, et al., Analysis of immune markers in human cardiac allograft recipients and association with coronary artery vasculopathy. J Heart Lung Transplant 2005; 24: 1606-1613.
27. De Vlaminck I, Valantine HA, Snyder TM, et al., Circulating cell-free DNA enables noninvasive diagnosis of heart transplant rejection. Sci Transl Med 2014; 6: 241ra277.
28. Hidestrand M, Tomita-Mitchell A, Hidestrand PM, et al., Highly sensitive noninvasive cardiac transplant rejection monitoring using targeted quantification of donor-specific cell-free deoxyribonucleic acid. J Am Coll Cardiol 2014; 63: 1224-1226.
29. Bruneau S, Woda CB, Daly KP, et al., Key features of the intragraft microenvironment that determine long-term survival following transplantation. Front Immunol 2012; 3: 54.
30. Einecke G, Sis B, Reeve J, et al., Antibody-mediated microcirculation injury is the major cause of late kidney transplant failure. Am J Transplant 2009; 9: 2520-2531.
31. Sis B, Halloran PF,. Endothelial transcripts uncover a previously unknown phenotype: C4d-negative antibody-mediated rejection. Curr Opin Organ Transplant 2010; 15: 42-48.
32. Sis B, Mengel M, Haas M, et al., Banff '09 meeting report: Antibody mediated graft deterioration and implementation of Banff working groups. Am J Transplant 2010; 10: 464-471.
33. Daly KP, Seifert ME, Chandraker A, et al., VEGF-C, VEGF-A and related angiogenesis factors as biomarkers of allograft vasculopathy in cardiac transplant recipients. J Heart Lung Transplant 2013; 32: 120-128.
34. Azimzadeh AM, Pfeiffer S, Wu GS, et al., Humoral immunity to vimentin is associated with cardiac allograft injury in nonhuman primates. Am J Transplant 2005; 5: 2349-2359.
35. Barber LD, Whitelegg A, Madrigal JA, Banner NR, Rose ML,. Detection of vimentin-specific autoreactive CD8+ T cells in cardiac transplant patients. Transplantation 2004; 77: 1604-1609.
36. Jurcevic S, Ainsworth ME, Pomerance A, et al., Antivimentin antibodies are an independent predictor of transplant-associated coronary artery disease after cardiac transplantation. Transplantation 2001; 71: 886-892.
37. Kalache S, Dinavahi R, Pinney S, Mehrotra A, Cunningham MW, Heeger PS,. Anticardiac myosin immunity and chronic allograft vasculopathy in heart transplant recipients. J Immunol 2011; 187: 1023-1030.
38. Rose ML,. Role of antibodies in transplant-associated cardiac allograft vasculopathy. Z Kardiol 2000; 89 (Suppl 9): IX/11-15.
39. Rose ML,. Role of anti-vimentin antibodies in allograft rejection. Hum Immunol 2013; 74: 1459-1462.
40. Hollander Z, Lin D, Chen V, et al., Whole blood biomarkers of acute cardiac allograft rejection: Double-crossing the biopsy. Transplantation 2010; 90: 1388-1393.
41. Lin D, Cohen Freue G, Hollander Z, et al., Plasma protein biosignatures for detection of cardiac allograft vasculopathy. J Heart Lung Transplant 2013; 32: 723-733.
42. Lin D, Hollander Z, Ng RT, et al., Whole blood genomic biomarkers of acute cardiac allograft rejection. J Heart Lung Transplant 2009; 28: 927-935.
43. Shannon CP, Hollander Z, Wilson-McManus J, et al., White blood cell differentials enrich whole blood expression data in the context of acute cardiac allograft rejection. Bioinform Biol Insights 2012; 6: 49-61.
44. Tuzcu EM, Kapadia SR, Sachar R, et al., Intravascular ultrasound evidence of angiographically silent progression in coronary atherosclerosis predicts long-term morbidity and mortality after cardiac transplantation. J Am Coll Cardiol 2005; 45: 1538-1542.
45. Stewart S, Winters GL, Fishbein MC, et al., Revision of the 1990 working formulation for the standardization of nomenclature in the diagnosis of heart rejection. J Heart Lung Transplant 2005; 24: 1710-1720.
46. Tuzcu EM, De Franco AC, Hobbs R, et al., Prevalence and distribution of transplant coronary artery disease: Insights from intravascular ultrasound imaging. J Heart Lung Transplant 1995; 14 (6 Pt 2): S202-S207.
47. Tuzcu EM, Hobbs RE, Rincon G, et al., Occult and frequent transmission of atherosclerotic coronary disease with cardiac transplantation. Insights from intravascular ultrasound. Circulation 1995; 91: 1706-1713.
48. Kapadia SR, Ziada KM, L'Allier PL, et al., Intravascular ultrasound imaging after cardiac transplantation: Advantage of multi-vessel imaging. J Heart Lung Transplant 2000; 19: 167-172.
49. Schoenhagen P, Sapp SK, Tuzcu EM, et al., Variability of area measurements obtained with different intravascular ultrasound catheter systems: Impact on clinical trials and a method for accurate calibration. J Am Soc Echocardiogr 2003; 16: 277-284.
50. Ashoor I, Najafian N, Korin Y, et al., Standardization and cross validation of alloreactive IFNgamma ELISPOT assays within the clinical trials in organ transplantation consortium. Am J Transplant 2013; 13: 1871-1879.
51. Sawinski D, Uribarri J, Peace D, et al., 25-OH-vitamin D deficiency and cellular alloimmunity as measured by panel of reactive T cell testing in dialysis patients. Am J Transplant 2010; 10: 2287-2295.
52. Eisen HJ, Kobashigawa J, Starling RC, et al., Everolimus versus mycophenolate mofetil in heart transplantation: A randomized, multicenter trial. Am J Transplant 2013; 13: 1203-1216.
53. Eisen HJ, Tuzcu EM, Dorent R, et al., Everolimus for the prevention of allograft rejection and vasculopathy in cardiac-transplant recipients. N Engl J Med 2003; 349: 847-858.
54. Kobashigawa JA, Pauly DF, Starling RC, et al., Cardiac allograft vasculopathy by intravascular ultrasound in heart transplant patients: Substudy from the Everolimus versus mycophenolate mofetil randomized, multicenter trial. JACC Heart Fail 2013; 1: 389-399.
55. Poggio ED, Augustine JJ, Clemente M, et al., Pretransplant cellular alloimmunity as assessed by a panel of reactive T cells assay correlates with acute renal graft rejection. Transplantation 2007; 83: 847-852.
56. Poggio ED, Clemente M, Hricik DE, Heeger PS,. Panel of reactive T cells as a measurement of primed cellular alloimmunity in kidney transplant candidates. J Am Soc Nephrol 2006; 17: 564-572.
57. Strom TB, Suthanthiran M,. Prospects and applicability of molecular diagnosis of allograft rejection. Semin Nephrol 2000; 20: 103-107.
58. Strom TB, Suthanthiran M,. Transcriptional profiling to assess the clinical status of kidney transplants. Nat Clin Pract Nephrol 2006; 2: 116-117.
59. Crespo-Leiro MG, Zuckermann A, Bara C, et al., Concordance among pathologists in the second Cardiac Allograft Rejection Gene Expression Observational Study (CARGO II). Transplantation 2012; 94: 1172-1177.
60. Yang HM, Lai CK, Gjertson DW, et al., Has the 2004 revision of the International Society of Heart and Lung Transplantation grading system improved the reproducibility of the diagnosis and grading of cardiac transplant rejection? Cardiovasc Pathol 2009; 18: 198-204.
61. Costanzo MR, Naftel DC, Pritzker MR, et al., Heart transplant coronary artery disease detected by coronary angiography: A multiinstitutional study of preoperative donor and recipient risk factors. Cardiac Transplant Research Database. J Heart Lung Transplant 1998; 17: 744-753.
62. Keogh AM, Valantine HA, Hunt SA, et al., Impact of proximal or midvessel discrete coronary artery stenoses on survival after heart transplantation. J Heart Lung Transplant 1992; 11: 892-901.
63. Kobashigawa JA, Tobis JM, Starling RC, et al., Multicenter intravascular ultrasound validation study among heart transplant recipients: Outcomes after five years. J Am Coll Cardiol 2005; 45: 1532-1537.
64. Mehra MR, Benza R, Deng MC, Russell S, Webber S,. Surrogate markers for late cardiac allograft survival. Am J Transplant 2004; 4: 1184-1191.
65. Mehra MR, Crespo-Leiro MG, Dipchand A, et al., International Society for Heart and Lung Transplantation working formulation of a standardized nomenclature for cardiac allograft vasculopathy-2010. J Heart Lung Transplant 2010; 29: 717-727.
66. Hartmann M, Huisman J, Bose D, et al., Serial intravascular ultrasound assessment of changes in coronary atherosclerotic plaque dimensions and composition: An update. Eur J Echocardiogr 2011; 12: 313-321.
67. Mintz GS, Maehara A,. Serial intravascular ultrasound assessment of atherosclerosis progression and regression. State-of-the-art and limitations. Circ J 2009; 73: 1557-1560.
68. Keslar KS, Lin M, Zmijewska AA, et al., Multicenter evaluation of a standardized protocol for noninvasive gene expression profiling. Am J Transplant 2013; 13: 1891-1897.
69. Nykanen AI, Sandelin H, Krebs R, et al., Targeting lymphatic vessel activation and CCL21 production by vascular endothelial growth factor receptor-3 inhibition has novel immunomodulatory and antiarteriosclerotic effects in cardiac allografts. Circulation 2010; 121: 1413-1422.
70. Kerjaschki D, Regele HM, Moosberger I, et al., Lymphatic neoangiogenesis in human kidney transplants is associated with immunologically active lymphocytic infiltrates. J Am Soc Nephrol 2004; 15: 603-612.
71. Carmeliet P,. Mechanisms of angiogenesis and arteriogenesis. Nat Med 2000; 6: 389-395.
72. Girnita DM, Brooks MM, Webber SA, et al., Genetic polymorphisms impact the risk of acute rejection in pediatric heart transplantation: A multi-institutional study. Transplantation 2008; 85: 1632-1639.
73. Torry RJ, Labarrere CA, Torry DS, Holt VJ, Faulk WP,. Vascular endothelial growth factor expression in transplanted human hearts. Transplantation 1995; 60: 1451-1457.
74. Nykanen AI, Krebs R, Saaristo A, et al., Angiopoietin-1 protects against the development of cardiac allograft arteriosclerosis. Circulation 2003; 107: 1308-1314.
75. Augustine JJ, Poggio ED, Clemente M, et al., Hemodialysis vintage, black ethnicity, and pretransplantation antidonor cellular immunity in kidney transplant recipients. J Am Soc Nephrol 2007; 18: 1602-1606.
76. Augustine JJ, Siu DS, Clemente MJ, Schulak JA, Heeger PS, Hricik DE,. Pre-transplant IFN-gamma ELISPOTs are associated with post-transplant renal function in African American renal transplant recipients. Am J Transplant 2005; 5: 1971-1975.
77. Hricik DE, Rodriguez V, Riley J, et al., Enzyme linked immunosorbent spot (ELISPOT) assay for interferon-gamma independently predicts renal function in kidney transplant recipients. Am J Transplant 2003; 3: 878-884.
78. Muthukumar T, Dadhania D, Ding R, et al., Messenger RNA for FOXP3 in the urine of renal-allograft recipients. N Engl J Med 2005; 353: 2342-2351.
79. Suthanthiran M, Schwartz JE, Ding R, et al., Urinary-cell mRNA profile and acute cellular rejection in kidney allografts. N Engl J Med 2013; 369: 20-31.
80. Hodges AM, Lyster H, McDermott A, et al., Late antibody-mediated rejection after heart transplantation following the development of de novo donor-specific human leukocyte antigen antibody. Transplantation 2012; 93: 650-656.
81. Kobashigawa J, Crespo-Leiro MG, Ensminger SM, et al., Report from a consensus conference on antibody-mediated rejection in heart transplantation. J Heart Lung Transplant 2011; 30: 252-269.
82. Smith JD, Banner NR, Hamour IM, et al., De novo donor HLA-specific antibodies after heart transplantation are an independent predictor of poor patient survival. Am J Transplant 2011; 11: 312-319.
83. Petrakopoulou P, Kubrich M, Pehlivanli S, et al., Cytomegalovirus infection in heart transplant recipients is associated with impaired endothelial function. Circulation 2004; 110 (11 Suppl 1): II207-II212.
84. Sharples LD, Jackson CH, Parameshwar J, Wallwork J, Large SR,. Diagnostic accuracy of coronary angiography and risk factors for post-heart-transplant cardiac allograft vasculopathy. Transplantation 2003; 76: 679-682.
85. Grattan MT, Moreno-Cabral CE, Starnes VA, Oyer PE, Stinson EB, Shumway NE,. Cytomegalovirus infection is associated with cardiac allograft rejection and atherosclerosis. JAMA 1989; 261: 3561-3566.